Photo of Richard D. Press, M.D., Ph.D.

Richard D. Press M.D., Ph.D.

    • Professor of Pathology School of Medicine
    • Director, Molecular Pathology and Molecular Diagnostics Laboratories
    • Molecular Genetic Pathology Fellowship Program Director
    • Molecular and Medical Genetics Graduate Program School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

Dr. Press is the director of molecular pathology and the Molecular Diagnostics Center at the OHSU Knight Cancer Institute, and program director for the molecular genetic pathology fellowship. His research interests include molecular diagnostic biomarkers in cancer and infectious diseases and prevalent genetic alterations in common diseases. Dr. Press received his M.D. and Ph.D. in 1988 at Case Western Reserve University in Cleveland.

Education

  • M.D., Ph.D., Case Western Reserve University, Cleveland Ohio 1988
  • B.A., Northwestern University, Evanston Illinois 1981
  • Residency:

    • Pathology, University of Pennsylvania, Philadelphia
  • Fellowship:

    • Molecular pathology, University of Pennsylvania, Philadelphia
  • Certifications:

    • Clinical Pathology, American Board of Pathology, 1992
    • Molecular Genetic Pathology, American Board of Pathology & American Board of Medical Genetics, 2001

Publications

  • "Measurement of BCR-ABL1 transcripts on the International Scale in the United States : current status and best practices." Leukemia and Lymphoma In: , Vol. 58, No. 1, 02.01.2017, p. 8-16.
  • "Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential." American Journal of Hematology In: , Vol. 92, No. 1, 01.01.2017, p. E6-E8.
  • "Highly accurate molecular genetic testing for HFE hereditary hemochromatosis : Results from 10 years of blinded proficiency surveys by the College of American Pathologists." Genetics in Medicine In: , Vol. 18, No. 12, 01.12.2016, p. 1206-1213.
  • "Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women." Experimental Hematology  In: , Vol. 44, No. 9, 01.09.2016, p. 857-865.e5.
  • "Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale." Leukemia In: , Vol. 30, No. 9, 01.09.2016, p. 1844-1852.
  • "Targeted next-generation sequencing in myelodysplastic syndrome and chronic myelomonocytic leukemia aids diagnosis in challenging cases and identifies frequent spliceosome mutations in transformed acute myeloid leukemia." American Journal of Clinical Pathology  In: , Vol. 145, No. 4, 01.04.2016, p. 497-506.
  • "Molecular methodologies and molecular pathology of hematolymphoid neoplasms."  Essentials of Anatomic Pathology: Fourth Edition. Springer International Publishing, 2016. p. 529-555.
  • "Molecular pathology of solid tumors."  Essentials of Anatomic Pathology: Fourth Edition. Springer International Publishing, 2016. p. 557-594.
  • "Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism." American Journal of Hematology  In: , Vol. 91, No. 2, 01.02.2016, p. 211-219.
  • "MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting." Annals of Hematology  In: , Vol. 94, No. 11, 22.11.2015, p. 1941-1944.
  • "The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients." Journal of Clinical Virology In: , Vol. 68, 01.07.2015, p. 1-5.
  • "Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia." Leukemia Research Reports In: , Vol. 3, No. 2, 01.01.2015, p. 67-69.
  • "Next generation sequencing in clinical diagnostics : Experiences of early adopters." Clinical Chemistry In: , Vol. 61, No. 1, 01.01.2015, p. 41-49.
  • "BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia." Cancer Cell  In: , Vol. 26, No. 3, 2014, p. 428-442.
  • "Clinical implementation of next-generation sequencing." Clinical Advances in Hematology and Oncology In: , Vol. 12, No. 4, 2014, p. 263-265.
  • "BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia." Journal of Molecular Diagnostics  In: , Vol. 15, No. 5, 09.2013, p. 565-576.
  • "Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia."  Methods in Molecular Biology. Vol. 999 2013. p. 1-23 (Methods in Molecular Biology; Vol. 999).
  • "Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia."  Methods in Molecular Biology. Vol. 999 2013. p. 25-39 (Methods in Molecular Biology; Vol. 999).
  • "BCR-ABL PCR testing in chronic myelogenous leukemia : Molecular diagnosis for targeted cancer therapy and monitoring." Expert Review of Molecular Diagnostics In: , Vol. 13, No. 7, 2013, p. 749-762.
  • "Multiplex high-throughput gene mutation analysis in acute myeloid leukemia." Human Pathology  In: , Vol. 43, No. 12, 12.2012, p. 2167-2176.
  • "TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms." Blood In: , Vol. 118, No. 24, 08.12.2011, p. 6392-6398.
  • "The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia." Blood In: , Vol. 118, No. 19, 10.11.2011, p. 5250-5254.
  • "Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms." American Journal of Clinical Pathology  In: , Vol. 135, No. 5, 05.2011, p. 709-719.
  • "Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA." Blood  In: , Vol. 116, No. 22, 25.11.2010.
  • "BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib." Blood In: , Vol. 116, No. 17, 28.10.2010, p. 3278-3285.
  • "Major molecular response in CML patients treated with tyrosine kinase inhibitors : The paradigm for monitoring targeted cancer therapy." Oncologist In: , Vol. 15, No. 7, 2010, p. 744-749.
  • "HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants." American Journal of Hematology In: , Vol. 84, No. 11, 11.2009, p. 710-714.
  • "Multi-site PCR-based CMV viral load assessment-assays demonstrate linearity and precision, but lack numeric standardization : A report of the association for molecular pathology." Journal of Molecular Diagnostics In: , Vol. 11, No. 2, 03.2009, p. 87-92.
  • "Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia." Journal of Molecular Diagnostics  In: , Vol. 11, No. 1, 01.2009, p. 4-11.
  • "Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib." Blood  In: , Vol. 114, No. 13, 2009, p. 2598-2605.

Additional information

Edit profile